Hervé Duchesne de Lamotte joins ExonHit
This article was originally published in Clinica
ExonHit Therapeutics (Paris, France), which is developing a blood test for Alzheimer's disease, has appointed Hervé Duchesne de Lamotte CEO. He has 25 years of international financial experience, including 10 years in the biotech industry. Mr de Lamotte previously managed Cirrus Management, a consultancy firm specialising in business and organisational strategies. Before that he was employed as chief operating officer for IDM Paris, part of the IDM group.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.